The FDA has approved a supplemental new drug application for Trintellix, which will now include labeling data from a randomized trial showing improved treatment-emergent sexual dysfunction, according to a press release. "Sexual dysfunction is one of the most common and bothersome side effects patients with depression struggle with when prescribed an SSRI," Dr. Anita Clayton, chair in the department of psychiatry & neurobehavioral sciences at UVA School of Medicine and study investigator, said. "We designed the study to specifically look at these troublesome side effects. Changing to a medi...